Executive record

Amy Burroughs

Director at Terns Pharmaceuticals

Follow
More
Challenge a Claim

Alpha ID: alpha:person:amy-burroughs-2Version: public-0As of: 2026-09-29

Not yet claimed11 published Claims4 sources
  • Director

Key Claims

Biography

Amy Burroughs has served as CEO and Director of Terns Pharmaceuticals since February 2024. She previously served as CEO and President of Cleave Therapeutics and as an Entrepreneur in Residence at 5AM Ventures. She holds a B.A. in computer science from Dartmouth College and an MBA from Harvard Business School.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Terns Pharmaceuticals

Current

Claims

Executive career

  1. 2025 to end not publishedExecutive title: Chief Executive Officer and Director · Organization not publishedTERN DEF 14A executive officers
  2. Dates not publishedExecutive title: Chief Executive Officer · Organization not publishedTERN DEF 14A director slate

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. TERN DEF 14A director slate

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 11, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 11, 2026
    • Board role: Board role: Director · Claim reviewed: May 11, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 11, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 11, 2026
    • Executive company: Executive at Terns Pharmaceuticals, Inc. · Claim reviewed: May 11, 2026
    • Executive title: Executive title: Chief Executive Officer · Claim reviewed: May 11, 2026
    • Technology background: Technology background reported in filings · Claim reviewed: May 11, 2026

  2. TERN DEF 14A executive officers

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 11, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 11, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 11, 2026
    • Executive company: Executive at Terns Pharmaceuticals, Inc. · Claim reviewed: May 11, 2026
    • Executive title: Executive title: Chief Executive Officer and Director · Claim reviewed: May 11, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 11, 2026

  3. Open source

    sec proxy · Source published: Apr 29, 2025 · Retrieved: May 10, 2026

    Supports 1 claim
    • Professional Role: Director at Terns Pharmaceuticals · Claim reviewed: May 11, 2026

  4. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Terns Pharmaceuticals · Claim reviewed: May 11, 2026